1-4 of 4
Michael Krueger
Close
Sort by
Journal Articles

Single Cell Transcriptome Comparisons of Diagnosis-Relapse Pairs Uncover Programs Associated with Chemoresistance in Pediatric AML

Mohammad Javad Najaf Panah, Tsz-Kwong Man, Michael Krueger, Pavel Sumazin, Michele S. Redell
Journal: Blood
Blood (2023) 142 (Supplement 1): 1574.
https://doi.org/10.1182/blood-2023-184926
Published: 2023
Journal Articles

Improved Relapse Prediction in Pediatric Acute Myeloid Leukemia By Deconvolving Lineage-Specific and Cancer-Specific Features in Single-Cell Data

Timothy James Keyes, Astraea Jager, Michael Krueger, Sylvia Plevritis, Robert Tibshirani, Richard Aplenc, Garry P. Nolan, Michele S. Redell, Kara L. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 6288–6289.
https://doi.org/10.1182/blood-2022-170939
Published: 2022
Journal Articles

Development of a Pediatric AML Patient Derived Xenograft Program

Alexandra McLean Stevens, Maci Terrell, Raushan Rashid, Jaime Omar Munoz, Alan K Gonzalez, Hailey H Oviedo, Tamilini Ilangovan, Michelle C Alozie, Michael Krueger, Kevin E. Fisher, Michele S. Redell
Journal: Blood
Blood (2022) 140 (Supplement 1): 11807–11808.
https://doi.org/10.1182/blood-2022-170348
Published: 2022
Journal Articles

Atovaquone Demonstrates Single Agent Activity and an Additive Effect in Combination with Cytotoxic Chemotherapy (Cytarabine and Daunorubicin) in AML

Alexandra McLean Stevens, MD, Jaime Omar Munoz, Michael Krueger, Terzah M. Horton, MD PhD, Michele Redell, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3899.
https://doi.org/10.1182/blood.V130.Suppl_1.3899.3899
Published: 2017